Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology. It is also developing MOVANTIK for opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives; ADYNOVATE for hemophilia A; Somavert to treat acromegaly; and Neulasta for treating neutropenia. In addition, the company develops PEG-INTRON for the treatment of hepatitis-C; Macugen for age-related macular degeneration; CIMZIA to treat rheumatoid arthritis, Crohn's disease, and psoriasis/ankylosing spondylitis; and MIRCERA for anemia related to chronic kidney disease in patients on and not on dialysis. Further, it is developing SEMPRANA to treat migraine; dapirolizumab pegol for systemic lupus erythematosus; PEGPH20 for ancreatic, non-small cell lung cancer, and other tumor types; and longer-acting blood clotting proteins for hemophilia. The company has collaboration agreement with AstraZeneca AB, Shire plc, Pfizer Inc., Amgen Inc., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Allergan, Inc., Halozyme Therapeutics, Inc., Baxalta Incorporated, Bristol-Myers Squibb Company, and Takeda Pharmaceutical Company Limited. The company was founded in 1990 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone415-482-5300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.71 million
Profitability
Miscellaneous
Employees509
OptionableOptionable
Nektar Therapeutics (NASDAQ:NKTR) Frequently Asked Questions
What is Nektar Therapeutics' stock symbol?
Nektar Therapeutics trades on the NASDAQ under the ticker symbol "NKTR."
How were Nektar Therapeutics' earnings last quarter?
Nektar Therapeutics (NASDAQ:NKTR) issued its quarterly earnings data on Wednesday, August, 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, topping the consensus estimate of $5.22 by $0.11. The biopharmaceutical company had revenue of $1.09 billion for the quarter, compared to analyst estimates of $1.03 billion. Nektar Therapeutics had a net margin of 59.71% and a return on equity of 79.66%. The business's revenue for the quarter was up 3043.7% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.39) EPS. View Nektar Therapeutics' Earnings History.
When is Nektar Therapeutics' next earnings date?
What price target have analysts set for NKTR?
10 Wall Street analysts have issued 12-month price objectives for Nektar Therapeutics' stock. Their forecasts range from $47.00 to $125.00. On average, they anticipate Nektar Therapeutics' stock price to reach $84.2222 in the next year. This suggests a possible upside of 95.7% from the stock's current price. View Analyst Price Targets for Nektar Therapeutics.
What is the consensus analysts' recommendation for Nektar Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nektar Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Nektar Therapeutics.
What are Wall Street analysts saying about Nektar Therapeutics stock?
Here are some recent quotes from research analysts about Nektar Therapeutics stock:
- 1. Mizuho analysts commented, "We attended a KOL dinner with Dr. Arlene Siefker-Radtke, a professor in the dept. of genitourinary medical oncology at MD Anderson treating ~160 patients/year. She was impressed by the depth of responses achieved across both PD-L1 (+) and (-) patients and by the conversion of patients from PD-L1 (-) to (+). She offered the analogy of a mini CAR-T" therapy to describe NKTR-214+Opdivo." (2/19/2019)
- 2. HC Wainwright analysts commented, "Our 12-month, $47 price target on shares of Nektar is based on a 13-year DCF-driven, sum-of-the-parts analysis. Our DCF is driven by beta of 1.14, terminal growth rate of 0.5%, risk premium of 4.93%, calculated WACC of 8.8%, and tax rate of 15% beginning in FY 2023. Cancer together represent about 71% of our target. In RCC, we assume commercial adoption in patients with PD-L1 expression at <1% (about 67% of the total clear cell RCC opportunity)."" (2/19/2019)
- 3. According to Zacks Investment Research, "Nektar has a promising pipeline with several pipeline and regulatory updates lined up for the next several quarters. Additionally, regular partnerships have enhanced the company’s financial position. Nektar stands to receive significant sales milestone payment plus royalties for Movantik, Adynovate and Neulasta under the license agreement with AstraZeneca, Shire and Amgen, respectively. Also, its recent co-development deal with Lilly for NKTR-358 and Bristol-Myers for NKTR-214 is encouraging. The deals provide revenues as well as reduce expenses by sharing research costs. On the flip side, Nektar relies heavily on partners for revenues. Partnership-related setbacks may thus weigh heavily on the company. Shares of the company have outperformed the industry in the past six months." (1/14/2019)
Has Nektar Therapeutics been receiving favorable news coverage?
News headlines about NKTR stock have been trending neutral on Wednesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Nektar Therapeutics earned a news sentiment score of 0.3 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days.
Who are some of Nektar Therapeutics' key competitors?
Some companies that are related to Nektar Therapeutics include Alexion Pharmaceuticals (ALXN), Shiseido (SSDOY), Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), Mylan (MYL), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS) and Beigene (BGNE).
Who are Nektar Therapeutics' key executives?
Nektar Therapeutics' management team includes the folowing people:
- Mr. Howard W. Robin, CEO, Pres & Director (Age 66)
- Mr. Gil M. Labrucherie, Sr. VP & CFO (Age 47)
- Mr. John Nicholson, Sr. VP & COO (Age 67)
- Dr. Stephen K. Doberstein, Chief R&D Officer (Age 60)
- Dr. Maninder Hora, Sr. VP of Pharmaceutical Devel. & Chief Technical Operations Officer (Age 65)
Who are Nektar Therapeutics' major shareholders?
Nektar Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.50%), First Trust Advisors LP (1.33%), Geode Capital Management LLC (1.29%), Northern Trust Corp (1.04%), Bank of New York Mellon Corp (0.82%) and BB Biotech AG (0.80%). Company insiders that own Nektar Therapeutics stock include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Ivan P Gergel, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Lutz Lingnau, Maninder Hora, R Scott Greer, Robert Chess, Roy A Whitfield and Stephen K Doberstein. View Institutional Ownership Trends for Nektar Therapeutics.
Which institutional investors are selling Nektar Therapeutics stock?
NKTR stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Advisers LP, Westfield Capital Management Co. LP, BlackRock Inc., Gotham Asset Management LLC, Tekla Capital Management LLC, Korea Investment CORP and Squarepoint Ops LLC. Company insiders that have sold Nektar Therapeutics company stock in the last year include Christopher A Kuebler, Dennis L Winger, Gil M Labrucherie, Howard W Robin, Jeffrey Robert Ajer, Jillian B Thomsen, John Nicholson, Maninder Hora, R Scott Greer, Robert Chess and Stephen K Doberstein. View Insider Buying and Selling for Nektar Therapeutics.
Which institutional investors are buying Nektar Therapeutics stock?
NKTR stock was purchased by a variety of institutional investors in the last quarter, including BB Biotech AG, State of New Jersey Common Pension Fund D, Voloridge Investment Management LLC, First Trust Advisors LP, Rhenman & Partners Asset Management AB, Bellevue Group AG, Dimensional Fund Advisors LP and Tocqueville Asset Management L.P.. View Insider Buying and Selling for Nektar Therapeutics.
How do I buy shares of Nektar Therapeutics?
Shares of NKTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nektar Therapeutics' stock price today?
One share of NKTR stock can currently be purchased for approximately $43.03.
How big of a company is Nektar Therapeutics?
Nektar Therapeutics has a market capitalization of $7.45 billion and generates $30.71 million in revenue each year. The biopharmaceutical company earns $-96,690,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis. Nektar Therapeutics employs 509 workers across the globe.
What is Nektar Therapeutics' official website?
How can I contact Nektar Therapeutics?
Nektar Therapeutics' mailing address is 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA, 94158. The biopharmaceutical company can be reached via phone at 415-482-5300 or via email at [email protected]
MarketBeat Community Rating for Nektar Therapeutics (NASDAQ NKTR)
MarketBeat's community ratings are surveys of what our community members think about Nektar Therapeutics and other stocks. Vote "Outperform" if you believe NKTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NKTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
